Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132405 · ClinicalTrials.gov registry record · Phase 2
Study of ALGRX 3268 for Needlestick Pain in Children
A Phase 2 study, sponsored by AlgoRx Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT00132405: Completed Phase 2 study, sponsored by AlgoRx Pharmaceuticals.
NCT00132405 is a Phase 2 study that has completed, run by AlgoRx Pharmaceuticals. The registered enrollment target is 260 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00132405, a Phase 2 study, has completed, sponsored by AlgoRx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
Minor needlestick procedures often cause significant pain and distress in children, yet interventions to reduce pain are used infrequently. ALGRX 3268 is a novel, single-use, prefilled, needle-free dispenser that immediately delivers powdered lidocaine into the epidermis and provides local analgesia in 2 to 3 minutes. The purpose of this prospective, randomized, double-blind, and placebo-controlled trial is to determine the efficacy and tolerability of ALGRX 3268 in children aged 3 to 18 years undergoing venipuncture. The trial will enroll a total of 306 children aged 3 to 18 years scheduled to undergo venipuncture of the back of the hand at a single study center.
Interventions
- DRUG ALGRX 3268
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2004-05 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
What the finished NCT00132405 record still lists
NCT00132405 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 1 intervention - of which ALGRX 3268 is the first listed.
NCT00132405 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00132405 about?
NCT00132405 is a clinical study titled "Study of ALGRX 3268 for Needlestick Pain in Children". Minor needlestick procedures often cause significant pain and distress in children, yet interventions to reduce pain are used infrequently. ALGRX 3268 is a novel, single-use, prefilled, needle-free dispenser that immediately delivers powdered lidocaine into the epidermis and provides local analgesia...
What is the current status of trial NCT00132405?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2004-05. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00132405?
The interventions under investigation include: ALGRX 3268 (DRUG).
Who is sponsoring clinical trial NCT00132405?
This trial is sponsored by AlgoRx Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00132405's enrollment target sits among peer trials
260 210th of 2000 higher than 1,789 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia